Dilute Russell's viper venom time reagents in lupus anticoagulant testing: a well-considered choice.

BACKGROUND

Lupus anticoagulant (LAC) detection represents diagnostic challenges among which the multitude of available reagents and interference by anticoagulant treatment. One of the two advised tests is the dilute Russell's viper venom time (dRVVT). However, it is currently not clear whether all dRVVT reagents may be considered equivalent. The objective of the study was to evaluate the diagnostic performance of two dRVVT reagents, with special attention to the influence of anticoagulant therapy.

METHODS

STA®-Staclot® dRVV Screen/Confirm (Stago, Asnières-sur-Seine, France) and dRVT-LS/dRVTL-LR (Haematex, Hornsby, Australia) were evaluated on 443 patient samples [358 consecutive patients with LAC request including six antiphospholipid syndrome (APS) patients, 18 non-consecutively selected APS patients and 37 vitamin K antagonists (VKA)-treated and 30 direct oral anticoagulants (DOAC)-treated non-APS patients]. Additionally, pooled normal plasma (PNP) was spiked with factor deficient plasma (n=33) and DOAC calibrators (n=21) to evaluate sensitivity for factor deficiencies and false-positivity rates, respectively.

RESULTS

A higher number of samples were defined as LAC positive by Stago vs. Haematex [11.5% (41/358) vs. 3.63% (13/358)]. Most discordances were in the VKA and DOAC group. Haematex was less prone to VKA-related factor deficiencies, explaining the absence of false-positive LAC results in VKA-treated non-APS patients compared to 10.8% with Stago. We observed no false-positive LAC ratios with Haematex in DOAC-spiked PNP and a lower number in DOAC-treated non-APS patients. However, increased specificity seemed to be at cost of a reduced sensitivity as Haematex showed less positive APS patient samples (45.8% vs. 87.5%).

CONCLUSIONS

dRVVT reagents differ in LAC sensitivity and for VKA and DOAC interference.